60 related articles for article (PubMed ID: 38572316)
1. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
Li J; Gong L; Li J; Gong Z; Wang X; Yan H; Zhang Y; Mao H; Chen K
Vaccine; 2024 Jul; 42(18):3751-3755. PubMed ID: 38714449
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.
Wang X; Zhang M; Wei K; Li C; Yang J; Jiang S; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Zhang W; Xie F; Wang P; Zhang Y
Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793715
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.
Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
bioRxiv; 2024 May; ():. PubMed ID: 38826376
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness.
Liu W; Huang Z; Xiao J; Wu Y; Xia N; Yuan Q
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399960
[TBL] [Abstract][Full Text] [Related]
7. The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape.
Kumar P; Jayan J; Sharma RK; Gaidhane AM; Syed Zahiruddin Q; Rustagi S; Satapathy P
QJM; 2024 Jun; ():. PubMed ID: 38867702
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Omicron subvariants from BA.2 to BA.2.86 and JN.1: strong lung infection ability and evolving immune escape capacity.
Hong B; Li M; Fan H
MedComm (2020); 2024 Jul; 5(7):e578. PubMed ID: 38882208
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron" [Cytokine Growth Factor Rev. 70 (2023) 13-25].
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2024 Jun; 77():117. PubMed ID: 38614914
[No Abstract] [Full Text] [Related]
10. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
11. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
12. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
Liu Q; Jin M; Mei F; Fan H; Gu M; Zhang Y; Qian S; Tan X; Ji L; Zhang Z; Chen G; Yan H; Chen Y; Lan K; Geng Q; Cai K; Zhou L
Front Cell Infect Microbiol; 2024; 14():1381877. PubMed ID: 38572316
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
14. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.
Toyoda M; Tan TS; Motozono C; Barabona G; Yonekawa A; Shimono N; Minami R; Nagasaki Y; Miyashita Y; Oshiumi H; Nakamura K; Matsushita S; Kuwata T; Ueno T
Microbiol Spectr; 2023 Aug; 11(4):e0066023. PubMed ID: 37310218
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
